Preparation, optimization, and characterization of topotecan loaded PEGylated liposomes using factorial design

Drug Development and Industrial Pharmacy

Volumn 34, Issue 1, 2008, Pages 10-23

  Vali, Amir Masoud ^a   Toliyat, Taiebeh ^b   Shafaghi, Bijan ^a   Dadashzadeh, Simin ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Conventional liposome; Factorial design; PEGylated liposome; Release kinetics; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; CHOLESTEROL; DISTEAROYL PHOSPHATIDYLETHANOLAMINE; DISTEAROYLPHOSPHATIDIC ACID; DISTEAROYLPHOSPHATIDYLCHOLINE; ETHANOLAMINE DERIVATIVE; LACTONE; LIPOSOME; MACROGOL; PHOSPHATIDYLGLYCEROL; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; DRUG RELEASE; DRUG RETENTION; DRUG STABILITY; DRUG SYNTHESIS; ENCAPSULATION; FACTORIAL DESIGN; HYDRATION; PARTICLE SIZE; ZETA POTENTIAL;

ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; LIPIDS; LIPOSOMES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; SOLUBILITY; SURFACE PROPERTIES; TOPOTECAN; UNILAMELLAR LIPOSOMES;

EID: 38549158347     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040701385055     Document Type: Article

References (40)

1. Biloti, D. N., Santana, M. H., Pessine, F. B. (2003). Lipid membrane with low proton permeability. Biochim. Biophys Acta., 1611, 1-4.
2. Broom, C. (1996). Clinical studies of topotecan. Ann. N. Y. Acad. Sci., 803, 264-271.
3. Burke, T. G., Mishra, A. K., Wani, M. C., & Wall, M. E. (1993). Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry, 32, 5352-5364.
4. Chang, C. W., Barber, L., Ouyang, C., Masin, D., Bally, M. B., & Madden, T. D. (1997). Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice. Br. J. Cancer, 75, 169-177.
5. Cullis, P. R., & Bally, M. B. (1989). Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res., 49, 5922-5930.
6. Cullis, P. R., Hope, M. J., Bally, M. B., Madden, T. D., & Mayer, L. D. (1987). Liposomes as pharmaceuticals. In: Ostro M. J. (Ed.), Liposomes: Rational design (pp. 39-72). New York: Marcel Dekkar.
7. Daemen, T., Regts, J., Meesters, M., Ten Kate, M. T., Bakker-Woudenberg, I. A. J. M., & Scherphof, G. L. (1997). Toxicity of doxorubicin entrapped within long-circulating liposomes. J. Control. Release, 44, 1-9.
8. Dunton, C. J. (1997). New options for the treatment of advanced ovarian cancer. Semin. Oncol., 24, S5-2-S5-11.
9. El-Gibaly, I., & Abdel-Ghaffar, S. K. (2005). Effect of hexacosanol on the characteristics of novel sustained-release allopurinol solid lipospheres (SLS): Factorial design application and product evaluation. Int. J. Pharm., 294, 33-51.
10. Emerson, D.L., (2000). Liposomal delivery of camptothecins. PSTT, 3, 205-209.
11. Fassberg, J., & Stella, V. J. (1992). A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci., 81, 676-684.
12. Franz, T. J. (1968). On the diffusion of tritiated water through skin. J. Invest. Dermatol., 50, 260.
13. Gabizon, A., Goren, D., Cohen, R., & Barenholz, Y. (1998). Development of liposomal anthracyclines: From basics to clinical applications. J. Control Release, 53, 275-279.
14. Gabizon, A., Isacson, R., Libson, E., Kaufman, B., Uziely, B., Catane, R., Ben-Dor, C. G., Rabello, E., Cass, Y., Peretz, T., Sulkes, A., Chisin, R., & Berenholz, Y. (1994). Clinical studies of liposome encapsulated doxorubicin. Acta Oncol., 33, 779-786.
15. Gregoriadis, G., 1988. Liposomes as drug carriers: Recent trends and progress. New York: John Wiley and Sons.
16. Hertzberg, R. P., Caranfa, M. J., Holden, H. G. (1989). Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J Med Chem, 32, 715-720.
17. Herzog, T. J. (2002). Update on the role of topotecan in the treatment of recurrent ovarian cancer. Oncologist, 7(Suppl. 5), 3-10.
18. Hochster, H., Liebes, L., & Speyer, J. (1994). Phase I trial of low-dose continuous TPT infusion in patients with cancer: An active and well-tolerated regimen. J. Clin. Oncology, 12, 553-559.
19. Hope, M. J., Bally, M. B., Webb, G., & Cullis, P. R. (1985). Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim. Biophys. Acta, 812, 55-65.
20. Kingsbury, W. D., Boehm, J. C., & Jakas, D. R. (1991). Synthesis of water-soluble (aminoalkyl)-camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J. Med. Chem. 34, 98-107.
21. Liebmann, J., Cook, J. A., Lipschultz, C., Teague, D., Fischer, J., & Mitchell, J. B. (1994). The influence of cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human cell lines. Cancer Chemother. Pharmacol., 33, 331-339.
22. Lim, H., Masin, D., Madden, T. D., & Bally, M. B. (1997). Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J. Pharmacol. Exp. Ther., 281, 566-573.
23. Maruyama, K., Okuizumi, S., Ishida, O., Yamauchi, H., Kikuchi, H., & Iwatsuru, M. (1994). Phosphatidyl polyglycerols prolong liposome circulation in vivo. Int. J. Pharm., 111, 103-107.
24. Mayer, L. D., Nayar, R., Thies, R. L., Boman, N. L., Cullis, P. R., & Bally, M. B. (1993). Identification of vesicle properties that enhance the anti-tumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother. Pharmacol., 33, 17-24.
25. Nygren, P., Csoka, K., Jonsson, B., Fridborg, H., Bergh, J., Hagberg, H., Glimelius, B., Brodin, O., Tholander, B., Kreuger, A., Lönnerholm, G., Jakobsson, A., Olsen, L., Kristensen, J., & Larsson, R. (1995). The cytotoxic activity of taxol in primary cultures of tumor cells from patients is partly mediated by cremophor EL. Br. J. Cancer, 71, 478-481.
26. Papahadjopoulos, D. (1999). Steric stabilization an overview. In Janoff, A. S. (Ed.), Liposomes rational design (pp. 1-12). New York: Marcel Dekker.
27. Pizzolato, J. F., & Saltz, L. B. (2003). The camptothecins. Lancet, 361, 2235-2242.
28. Ritger, P. L., & Peppas, N. A. (1987). A simple equation for description of solute release. I. Fickian and non-Fickian release from nonswellable devices in the form of slabs, spheres, cylinders or discs. J. Control. Rel., 5, 23-36.
29. Rowinsky, E. K., & Donehower, R. C. (1995). Paclitaxel (Taxol). N. Engl. J. Med., 332, 1004-1014.
30. Santana, V. M., Zamboni, W. C., Kirstein, M. N., Tan, M., Liu, T., Gajjar, A., Houghton, P. J., & Stewart, C. F. (2003). A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res., 9, 633-640.
31. Santos, N. D., Waterhouse, D., Masin, D., Tardi, P. G., Karlsson, G., Edwards, K., & Bally, M. B. (2005). Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. J. Control. Release, 105, 89-105.
32. Sharma, A., & Straubinger, R. M. (1994). Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm. Res., 11, 889-896.
33. Sharma, U. S., Balasubramanian, S. V., & Straubinger, R. M. (1995). Pharmaceutical and physical properties of paclitaxel (taxol) complexes with cyclodextrins. J. Pharm. Sci., 84, 1223-1230.
34. Siepmann, J., & Peppas, N. A. (2003). Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Del Rev, 48, 139-157.
35. Sykes, E., Woodburn, K., Decker, D., & Kessel, D. (1994). Effects of Cremophor EL on distribution of Taxol to serum lipoproteins. Br. J. Cancer, 70, 401-404.
36. Unezaki, S., Maruyama, K., Ishida, O., Suginaka, A., Hosoda, J., & Iwatsuru, M. (1995). Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphipatic poly(ethylene glycol). Int. J. Pharm., 126, 41-48.
37. Vali, A. M., Shafaghi, B., & Dadashzadeh, S. (2005). Simple and sensitive high performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of topotecan in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci., 818, 205-212.
38. Webb, M. S. Harasym, T. O., Masin, D., Bally, M. B., & Mayer, L. D. (1995). Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetics and therapeutic properties of vincristine in murine and human tumor models. Br. J. Cancer, 72, 896-904.
39. Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. L., Trump, D., Baker, J. R., VanEcho, D. A., VonHoff, D. D., & Leyland-Jones, B. (1990). Hypersensitivity reactions from taxol. J. Clin. Oncol., 8, 1263-1268.
40. Zhang, J. Q., Zhang, Z. R., Yang, H., Tan, Q. Y., Qin, S. R., & Qiu, X. L. (2005). Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: In vitro and in vivo studies. Pharm Res., 22, 573-583.